A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2313-2326

  Vaidyanathan, Sujata ^a   Maboudian, Mojdeh ^a   Warren, Vance ^a   Yeh, Ching Ming ^a   Dieterich, Hans Armin ^a   Howard, Dan ^a   Dole, William P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Antihypertensives; Drug interaction; Lipid lowering; Pharmacokinetics; Type 2 Diabetes mellitus

Indexed keywords

ALISKIREN; DRUG METABOLITE; FENOFIBRATE; HYDROXYPIOGLITAZONE; KETOPIOGLITAZONE; METFORMIN; PIOGLITAZONE; RENIN INHIBITOR;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EOSINOPHIL; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INFECTION; INFESTATION; LIPID BLOOD LEVEL; LYMPHOCYTE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MONOTHERAPY; MORNING DOSAGE; NEUROLOGIC DISEASE; NEUTROPHIL; NORMAL HUMAN; ORTHOSTATIC BLOOD PRESSURE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINUS BRADYCARDIA; T WAVE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DRUG INTERACTIONS; FEMALE; FUMARATES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROCETOFEN; RENIN; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 50149092635     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802259354     Document Type: Review

References (49)

1. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705
2. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8
3. Tekturna. US prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2007
4. Rasilez. EU summary of product characteristics. Novartis Europharm Ltd, Horsham, W Sussex, UK, 2007
5. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8
6. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997-1005
7. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63
8. Pool JL, Gradman AH, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006;27(Suppl): 119 P-790
9. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens 2007;9(Suppl A):Al82 P-436
10. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004;10:163-70
11. Weycker D, Nichols GA, O'Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 2007;20:599-607
12. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
13. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
14. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-72
15. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72
16. Uresin Y, Taylor A, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8
17. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35:1418-28
18. Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46:661-75
19. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47:192-200
20. Dieterich H-A, Kemp C, Vaidyanathan S, et al. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2007;79:PIII-24
21. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433-6
22. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527-35
23. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343-56
24. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008;47:570-8
25. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45:1125-34
26. Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3-9
27. Zhong WZ, Williams MG. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J Pharm Biomed Anal 1996;14:465-73
28. Guidance for Industry: In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling: FDA/Center for Drug Evaluation and Research; 2001
29. Bailey CJ. Metformin - an update. Gen Pharmacol 1993;24:1299-309
30. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005;28:601-31
31. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102:99-110
32. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
33. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007; 18:18-25
34. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74
35. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56
36. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1-12
37. Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51
38. Vaidyanathan S, Jin Y, Schiller H, et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol 2005;97:239
39. Vaidyanathan S, Jarugula V, Dieterich H-A, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008 [in press]
40. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54:2460-70
41. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34:155-62
42. Ehrhardt M, Lindenmaier H, Burhenne J, et al. Influence of lipid lowering fibrates on p-glycoprotein activity in vitro. Biochem Pharmacol 2004;67:285-92
43. Vaidyanathan S, Reynolds C, Yeh C-M, et al, The pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with the p-glycoprotein modulators ketoconazole, digoxin and atorvastatin in healthy subjects. Clin Pharmacol Ther 2007;81(Suppl 1):S109 PIII-75
44. Rautio J, Humphreys JE, Webster LO, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006; 34:786-92
45. Ayalasomayajula S, Tchaloyan S, Yeh C-M, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008;24:717-26
46. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503
47. Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87:5503-6
48. Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;356:1279-89
49. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8